FDA Has Approved A New Medication Treatment For Migraines In Adults

Updated Feb 6, 2025 | 05:09 PM IST

SummaryMany people use the terms ‘migraine’ and ‘headache’ interchangeably. This leads many people to believe that migraines are not as serious as people make them out to be, and that cannot be more wrong, migraines have a major effect on a person’s lifestyle and the new approved medication may prove to be a great relief!
(Credit-Canva)

(Credit-Canva)

Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

End of Article

India To Launch First Indigenous H5N1 Vaccine For Chickens As Bird Flu Cases Recur: How Can It Help?

Updated Nov 18, 2026 | 07:00 PM IST

SummaryScientists at ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), Bhopal developed India's first ever inactivated vaccine to immunise poultry and prevent bird flu.
India To Launch First Indigenous H5N1 Vaccine For Chickens As Bird Flu Cases Recur: How Can It Help?

Credit: AI

India is set to launch its first indigenously developed vaccine against H5N1 bird flu virus in chickens on November 20, as new outbreaks have been emerging in different parts of the country.

Developed by scientists at ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), the inactivated vaccine targets H5N1 Clade 2.3.2.1a, a strain that caused several bird flu outbreaks among chickens in India.

According to the Ministry of Agriculture and Farmers' Welfare, this marks a significant development in poultry and public health as there is no commercial vaccine against this particular H5N1 strain.

Why India Developed A Bird Flu Vaccine For Chickens?

Bird flu, medically known as avian influenza, is a viral infection that primarily affects birds. Highly pathogenic avian influenza (HPAI) strains, including H5N1, can cause severe illness and extremely high mortality among infected poultry.

Since the first detection of bird flu in India in 2006, the country has reported more than 500 combined outbreaks involving H5N1 and H5N8 subtypes.

These outbreaks can have serious economic consequences. Infected birds may need to be culled to prevent further transmission. The 2006 outbreak alone resulted in estimated direct and indirect losses of Rs 2,200–3,000 crore.

The newly developed vaccine can help strengthen the country’s ability to prevent outbreaks and protect poultry populations against the H5N1 strain currently circulating in the country.

Also read: UK Reports Its First Human Case Of Bird Flu

H5N1 Vaccine & Bird Flu Outbreaks In India

The indigenous vaccine contains an inactive version of the virus that cannot replicate and infect. When administered, it exposes the chicken's immune system to viral components, just enough to allow it to recognise the virus and develop an immune response.

If the vaccinated bird encounters the actual virus later, its immune system can recognise it and respond more effectively.

The vaccine announcement comes just as fresh reports of bird flu infections in poultry have emerged.

In Tamil Nadu's Cuddalore district, H5N1 infections were confirmed following sudden deaths among chickens at poultry farms. More than 35,000 birds had died by November 13, prompting authorities to initiate containment and culling efforts.

Andhra Pradesh has also reported H5N1 infections in poultry, prompting restrictions and surveillance measures.

The indigenous vaccine is an important step in India's poultry disease-control efforts, but its introduction does not mean bird flu outbreaks will be prevented completely.

Its effectiveness depends on vaccination coverage, administration, monitoring of viral strains and compliance with farm biosecurity measures.

Also read: New Strain Of Bird Flu Detected In US, Here’s How You Can To Stay Protected

Can Bird Flu Spread From Chickens To Humans?

Although H5N1 primarily affects birds, the virus can occasionally cross the zoonotic barrier and infect humans, especially those who have long-term contact with infected birds, their secretions or contaminated environments.

Human infections can cause symptoms ranging from mild respiratory illness to severe pneumonia and, in some cases, death.

According to the World Health Organization (WHO), 1,003 human cases of H5N1 infection, including 479 deaths, had been reported across 25 countries since 2003, as cited in the Indian government's November 18 announcement.

Human infections, however, remain relatively uncommon and sustained human-to-human transmission has not been established.

People working with poultry should avoid handling sick or dead birds without protective equipment. Unusual bird deaths should be reported to veterinary authorities.

End of Article

Lung Cancer Survival Improves By 71% In US: But 1 In 5 Patients Still Gets No Treatment

Updated Nov 18, 2026 | 06:00 PM IST

SummaryThe American Lung Association's annual report found that despite improved survival rates, 20.9% of lung cancer patients receive no treatment, only 29.3% are diagnosed early and just 24.4% of eligible people undergo screening.
Lung Cancer Survival Improves By 71% In US: But 1 In 5 Patients Still Gets No Treatment

Credit: iStock

Lung cancer remains the leading cause of cancer deaths in the US, with 229,410 new cases expected this year, according to a annual report from the American Lung Association's (ALA).

The Association's ninth annual State of Lung Cancer report stated that although five-year survival has improved, low screening rates, delayed diagnosis and unequal access to treatment remain major challenges.

Harold Wimmer, President and CEO of the ALA, said, “the national five-year survival rate has increased significantly, from 18.1% to 31.0%, and screening rates have also continued to rise.”

However, he warned that progress has not reached all communities equally.

“Awareness is still low and challenges remain. We must continue to drive progress on lung cancer screening, comprehensive biomarker testing, clinical trials and effective treatments to help people live longer, fuller lives after a lung cancer diagnosis.”

One In Five Lung Cancer Patients Receives No Treatment

Only 29.3% of lung cancer cases are diagnosed early. Rhode Island recorded the highest early diagnosis rate at 38%, while Hawaii had the lowest at 21.9%.

More concerning, 20.9% of patients received no treatment. The ALA identified potential barriers including lack of awareness, stigma, fatalism after diagnosis and treatment costs.

No-treatment rates ranged from 13.4% in Rhode Island to 36.7% in Nevada.

Only 1 In 4 Eligible People Gets Screened

Annual low-dose CT scans can detect lung cancer early in people at high risk. Yet only 24.4% of eligible Americans underwent screening.

Massachusetts recorded the highest screening rate at 38.7%, while South Dakota had the lowest at 13.5%.

Other Key Findings

  • The US is expected to record 229,410 new lung cancer cases this year, with an incidence rate of 52.1 per 100,000 people. Utah had the lowest rate (24.6), while Kentucky had the highest (83.9).
  • The five-year survival rate stands at 31%. Massachusetts recorded the highest rate (40.9%), while Alabama had the lowest (23.8%).
  • Only 21.4% of patients underwent surgery. Massachusetts had the highest surgical treatment rate (32.7%), while New Mexico had the lowest (12.7%).
  • Biomarker testing helps identify suitable targeted therapies and immunotherapies. Nineteen states mandate insurance coverage for comprehensive testing, seven require partial coverage, while 24 states and Washington, D.C., have no such mandate.
  • Racial disparities persist, with people of color less likely to receive early diagnoses or surgery and more likely to receive no treatment than white patients.

What Increases The Risk Of Lung Cancer?

Smoking is a major risk factor. Others include radon gas, air pollution and secondhand smoke. The ALA recommends radon testing, reducing air pollution and stronger tobacco-control measures, including smoke-free laws and access to smoking cessation services.

Why Is Lung Cancer Often Diagnosed Late?

Cleveland Clinic defines lung cancer as a malignant disease that happens when cells in the lung tissue grow out of control and form tumors. It is the leading cause of cancer deaths worldwide.

Lung cancer may cause no noticeable symptoms in its early stages. Symptoms can include persistent cough, coughing up blood, chest pain, unexplained weight loss, shortness of breath, recurrent chest infections and fatigue.

These symptoms should not be ignored. Early detection improves the chances of successful treatment, particularly before the cancer spreads.

End of Article

ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

Updated Nov 18, 2026 | 05:04 PM IST

SummaryIndia is facing widespread antibiotic resistance, with several drugs showing low effectiveness against bacteria such as E. coli, Klebsiella pneumoniae and Salmonella. The ICMR's 2025 report also flags resistance to powerful antibiotics, including carbapenems, across participating hospitals.
ICMR Flags Widespread Antibiotic Resistance Across India: From E. coli To Typhoid, Which Drugs Are Failing?

Credit: iStock

Several antibiotics used to treat infections caused by E. coli and Klebsiella pneumoniae—bacteria linked to pneumonia, urinary tract and bloodstream infections—are showing low susceptibility in India, with resistance also reported to powerful drugs such as carbapenems, according to a new Indian Council of Medical Research (ICMR) report.

The newly released ICMR Antimicrobial Resistance Surveillance and Research Network (AMRSN) Annual Report 2025 assesses the distribution of bacterial pathogens and their susceptibility to different antibiotics.

The surveillance covers Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa, as well as Gram-positive bacteria such as Staphylococcus aureus and Enterococcus species.

For the first time, the report included data from 34 secondary-care hospitals, highlighting that antibiotic resistance is a concern beyond large, specialised hospitals.

The findings underscore the need for better diagnostics, responsible antibiotic use and stronger infection prevention.

"Antibiotic resistance is no longer a distant threat—it is affecting patients and families across India," Dr Neha Rastogi Panda, Senior Consultant, Infectious Diseases, Fortis Hospital, Gurugram, told HealthandMe.

Also read: Antimicrobial Resistance Could Contribute To 39 Million Deaths By 2050: WHO

Key Findings From The ICMR Report

The report highlighted several concerning resistance patterns across bacterial pathogens, including:

1. E. coli: Low susceptibility to cefotaxime and ceftazidime

The report showed that susceptibility of E. coli isolates to third-generation cephalosporins was low, with only 18.4% and 24.7% susceptible to cefotaxime and ceftazidime, respectively.

Low susceptibility was also observed among isolates from outpatient department (OPD) patients, suggesting that resistance to these antibiotics is widespread in the community and indicating a high prevalence of antibiotic-blocking enzymes.

2. K. pneumoniae: Low susceptibility to piperacillin-tazobactam and carbapenems

K. pneumoniae showed an alarmingly high resistance profile, with only 29.2% susceptible to piperacillin-tazobactam, 23–27% to third-generation cephalosporins, and only 35–40% to carbapenems.

Amikacin susceptibility was limited to 44.5%, while susceptibility to ceftazidime-avibactam was 37.7%. Tigecycline showed higher susceptibility, at 79.3%.

3. E. coli: Ceftriaxone susceptibility falls in secondary-care hospitals

Ceftriaxone susceptibility declined from 39.8% in Category I to 28.0% in Category II and 11.5% in Category III hospitals, indicating a high prevalence of resistance to third-generation cephalosporins even in smaller hospitals.

Meropenem susceptibility also declined across the three categories, from 80.3% to 77.5% and 67.1%, respectively.

Read more: Nearly 1 In 2 Patients Die, Treatment Costs Rise By 46%: ICMR Study Reveals Impact Of Drug-Resistant Infections

4. Acinetobacter baumannii: High carbapenem resistance

A high prevalence of carbapenem resistance was observed among A. baumannii, with 91.1% of revived isolates exhibiting carbapenem resistance, highlighting a substantial therapeutic and infection-control challenge.

OXA-23 was the predominant carbapenemase determinant, with frequent detection of OXA-23 and NDM co-profiles.

5. Salmonella Typhi and Salmonella Paratyphi A: Very low ciprofloxacin susceptibility

Fluoroquinolone susceptibility was lowest among the antibiotics assessed for both pathogens. Ciprofloxacin susceptibility was observed in only 2.0% of S. Typhi isolates and 0.4% of S. Paratyphi A isolates.

How Can We Prevent Antibiotic Resistance?

Dr Rastogi Panda warned that every time an antibiotic is misused, it increases the risk of making future infections harder to treat.

She advised people to:

  • Never take antibiotics without a doctor's prescription.
  • Never share antibiotics or use leftover tablets.
  • Take antibiotics exactly as prescribed.
  • Remember that antibiotics do not work against viral infections such as colds and flu.

"Cancer patients, ICU patients, the elderly and those with weakened immunity are particularly vulnerable. Responsible antibiotic use, vaccination and good hand hygiene can save lives. Protect antibiotics today, so they protect us tomorrow," the expert said.

End of Article